CA
CARM.US Carisma Therapeutics Inc.
- Market cap
- USD 16.7K
- P/E
- 0.0x
- P/B
- 114.10x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2025.
Is CARM.US undervalued?
Graham numberThe Graham number of Carisma Therapeutics Inc. cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Carisma Therapeutics Inc. fundamental analysis
No fundamental analysis for Carisma Therapeutics Inc. yet.
Carisma Therapeutics Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Carisma Therapeutics Inc.
Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, …
Full company profileCarisma Therapeutics Inc. financial statements
2025 annualized: Fiscal year 2025 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2025, the balance sheet is the latest quarter. Figures change when the annual report is published.
Carisma Therapeutics Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 990K | 30.0M | 425K | - | - | 11.2M | 26.5M | 9.83M | 14.9M | 19.6M | 65.3M |
| Gross Profit | 990K | 30.0M | 425K | -208K | -219K | 11.2M | 26.5M | 9.83M | -59.2M | -40.0M | 64.8M |
| Operating Income | -35.2M | 6.17M | -20.0M | -25.7M | -36.9M | -28.4M | -28.2M | -56.2M | -88.7M | -62.2M | 38.3M |
| EBITDA | -31.7M | 2.32M | -28.7M | -33.5M | -107M | -27.9M | -7.93M | -52.0M | -85.9M | -56.8M | 40.8M |
| Net Income | -33.5M | 1.89M | -29.0M | -33.7M | -108M | -28.3M | -336K | -61.2M | -86.9M | -60.5M | 34.2M |
| EPS | -35 | 1.74 | -22 | -11 | -24 | -4.80 | -0.04 | -1.52 | -2.59 | -1.46 | 0.82 |
| Balance Sheet | |||||||||||
| Total Assets | 36.8M | 104M | 75.1M | 112M | 114M | 188M | 313M | 72.2M | 89.6M | 30.5M | 6.55M |
| Total Liabilities | 17.9M | 65.4M | 57.1M | 67.4M | 141M | 198M | 141M | 215M | 63.0M | 58.4M | 7.42M |
| Shareholders' Equity | 18.9M | 38.7M | 18.0M | 44.2M | -26.7M | -9.23M | 172M | -157M | 26.5M | -27.9M | -867K |
| Cash & Short-term Investments | 36.1M | 25.3M | 14.7M | 50.4M | 48.1M | 55.4M | 163M | 52.0M | 77.6M | 18.8M | 2.78M |
| Total Debt | 13.9M | - | - | - | - | 3.45M | 2.63M | 40.2M | 3.12M | 2.48M | 762K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -34.5M | 2.62M | -17.8M | -22.8M | -37.5M | -27.0M | -37.3M | -7.57M | -81.2M | -59.9M | -18.8M |
| Capital Expenditure | 287K | 0.00 | 0.00 | 2.00K | 136K | 440K | 1.87M | 4.66M | 1.13M | 123K | 0.00 |
| Free Cash Flow | -34.8M | 2.62M | -17.8M | -22.8M | -37.7M | -27.5M | -39.2M | -12.2M | -82.3M | -60.0M | -18.8M |
| Ratios | |||||||||||
| ROE | -176.6% | 4.9% | -161.0% | -76.2% | - | - | -0.2% | - | -327.4% | - | - |
| ROA | -90.8% | 1.8% | -38.7% | -30.2% | -94.0% | -15.0% | -0.1% | -84.9% | -97.0% | -198.6% | 522.4% |
| Net Profit Margin | -3,379.0% | 6.3% | -6,830.4% | - | - | -252.3% | -1.3% | -622.6% | -582.3% | -308.1% | 52.4% |
| Debt to Equity | 0.73x | - | - | - | - | - | 0.02x | - | 0.12x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Carisma Therapeutics Inc. dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 147K | 0.02 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
| 2016 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:20 on Mar 8, 2023.
Who owns Carisma Therapeutics Inc.
- Insiders 23.04%
- Institutions 10.79%
- Public & others 66.17%
- Shares outstanding 41.8M
- Free float 30.1M
Carisma Therapeutics Inc. company profile
- Company name
- Carisma Therapeutics Inc.
- Ticker
- CARM.US
- Exchange
- USA Stocks
- Listed since
- Feb 6, 2014
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 46
- Fiscal year end
- December
- Address
- 3675 Market Street, Philadelphia, PA, United States, 19104
- Phone
- 267 491 6422
- Website
- carismatx.com
About Carisma Therapeutics Inc.
Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others. In addition, it develops in vivo CAR-M cell therapy to treat solid tumors, including hepatocellular carcinoma. Carisma Therapeutics, Inc. has collaboration and license agreement with ModernaTX, Inc. to address oncology gene therapies. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. Carisma Therapeutics, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.
Carisma Therapeutics Inc. management
2- Dr. Saar Gill M.D., Ph.D.Co-Founder & Chairman of Scientific Advisory Board
- Ms. Natalie McAndrewVice President of Finance · born 1974